Danaher Co. (NYSE:DHR) Shares Purchased by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC raised its position in Danaher Co. (NYSE:DHR) by 2.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,902 shares of the conglomerate’s stock after purchasing an additional 600 shares during the quarter. Marble Harbor Investment Counsel LLC’s holdings in Danaher were worth $5,257,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rialto Wealth Management LLC bought a new stake in Danaher during the 4th quarter valued at $34,000. HM Payson & Co. raised its stake in shares of Danaher by 7.9% during the fourth quarter. HM Payson & Co. now owns 142,515 shares of the conglomerate’s stock valued at $32,714,000 after purchasing an additional 10,417 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in Danaher in the fourth quarter worth about $712,000. Banco Santander S.A. grew its position in Danaher by 56.2% in the 4th quarter. Banco Santander S.A. now owns 8,757 shares of the conglomerate’s stock valued at $2,010,000 after buying an additional 3,151 shares in the last quarter. Finally, Camden National Bank increased its stake in Danaher by 285.0% during the 4th quarter. Camden National Bank now owns 7,227 shares of the conglomerate’s stock valued at $1,659,000 after buying an additional 5,350 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.1 %

NYSE:DHR opened at $212.35 on Friday. The business’s fifty day moving average price is $222.51 and its 200 day moving average price is $243.02. The firm has a market capitalization of $151.77 billion, a price-to-earnings ratio of 40.22, a PEG ratio of 2.66 and a beta of 0.82. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the business posted $2.09 EPS. On average, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. Danaher’s dividend payout ratio is presently 24.24%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on DHR shares. Robert W. Baird reduced their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Barclays dropped their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.